Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Infectious Agents and Cancer

Volumn 6, Issue 1, 2011, Pages

  Banura, Cecily ^a   Mirembe, Florence M ^a   Katahoire, Anne R ^a   Namujju, Proscovia B ^b,c   Mbonye, Anthony K ^d   Wabwire, Fred M ^a  

^a MAKERERE UNIVERSITY   (Uganda)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d MINISTRY OF HEALTH   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

CIRCUMCISION; GENOTYPE; HUMAN; INFECTION PREVENTION; INFECTION RISK; MORBIDITY; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SEXUALITY; UGANDA; VERRUCA VULGARIS; VIRUS DETECTION; WART VIRUS;

EID: 79960165083     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-6-11     Document Type: Review

References (60)

1. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Ferlay J, Bray F, Parkin MD, IARC cancer Base. No. 5 version 2.0 IARC, Lyon 2004
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Mũoz N, J Pathol 1999 189 1 12 9 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
3. Epidemiology of genital human papillomavirus infection. Koutsky L, Am J Med 1997 102 5A 3 8 9217656 (Pubitemid 127695953)
4. Chapter 5: Updating the natural history of HPV and anogenital cancer. Moscicki AB, Schiffman M, Kjaer S, Villa LL, Vaccine 2006 24 Suppl 3 3/42 51
5. Human Papillomavirus Prevalence and Type Distribution in Male Anogenital Sites and Semen. Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss MR, Dunne EF, Markowitz LE, Giuliano AR, Cancer Epidemiol Biomarkers Prev 2007 16 6 1107 14 http://cebp.aacrjournals.org/content/16/6/1107.abstract-target-2 10.1158/1055-9965.EPI-06-0997 17548671 (Pubitemid 46984945)
6. IARC, http://globocan.iarc.fr
7. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Mũoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM, the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, N Eng J Med 2003 348 518 27 10.1056/NEJMoa021641 (Pubitemid 36159887)
8. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Lacey CJN, Lowndes CM, Shah KV, Vaccine 2006 24S3 3/35 S3/41
9. The WHO/ICO Information Centre on HPV and Cervical Cancer. http://www.who.int/hpvcentre/en/
10. Global Cancer Statistics, 2002. Parkin MD, Bray F, Ferlay J, Pisani P, CA: A Cancer J Clinicians 2005 55 2 74 108 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
11. Cervical cancer vaccine. Cervical cancer. PATH, http://www.path.org/ projects/cervical-cancer-vaccine.php
12. HPV-vaccine and screening programs: the new era of global prevention. Mariani L, J Preve Med Hyg 2009 50 90 5
13. Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. Cope U, Hildesheim A, Schiffman MH, Manos MM, Lorincz AT, Burk RD, Glass AG, Greer C, Buckland J, Helgesen K, Scott DR, Sherman ME, Kurman RJ, Liaw KL, J Clin Microbiol 1997 35 9 2262 5 9276398 (Pubitemid 27349792)
14. Results of the First World Health Organization International Collaborative Study of Detection of Human Papillomavirus DNA. Quint W, Pagliusi SR, Lelie N, de Villiers EM, Wheeler CM, the World Health Organization Human Papillomavirus DNA International Collaborative Study Group, J Clin Microbiol 2006 44 2 571 9 10.1128/JCM.44.2.571-579.2006 16455914 (Pubitemid 43222253)
15. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M, Int J Cancer 2006 118 1 243 5 10.1002/ijc.21299 16032705 (Pubitemid 41681605)
16. Infection with human papillomavirus and HIV among young women in Kampala, Uganda. Banura C, Franceschi S, Doorn LJ, Arslan A, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E, J Infect Dis 2008 197 4 555 62 10.1086/526792 18237268 (Pubitemid 351321533)
17. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, Rwambuya S, Walker CJ, Kambugu FS, Abdul-Karim FW, Whalen CC, Salata RA, J Med Virol 2007 79 6 758 65 10.1002/jmv.20817 17457908 (Pubitemid 46709371)
18. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, Mbidde EK, Quint W, Weiderpass E, Int J Cancer 2008 123 9 2180 7 10.1002/ijc.23762 18711697
19. Human papillomavirus prevalence and cytopathology correlation in young Ugandan women using a low-cost liquid-based Pap preparation. Taube JM, Kamira B, Motevalli M, Nakabiito C, Lukande R, Kelly DP, Erozan YS, Gravitt PE, Buresh ME, Mmiro F, Bagenda D, Guay LA, Jackson JB, Diagn Cytopathol 2010 38 8 555 63 19937939
20. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R, Sex Transm Infect 2008 84 306 311 http://sti.bmj.com/content/84/4/306.abstract- aff-1 10.1136/sti.2007.027318 18385223
21. Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda. Asiimwe S, Whalen CC, Tisch DJ, Tumwesigye E, Sethi AK, Int J STD AIDS 2008 19 9 605 10 10.1258/ijsa.2008. 008025 18725551
22. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Clifford G, Smith JS, Aguado T, Franceschi S, British J Cancer 2003 89 101 5 10.1038/sj.bjc.6601024 (Pubitemid 36897943)
23. Age-specific prevalence of infection with human papillomavirus in females: a global review. Smith JS, Melendy A, Rana RK, Pimenta JM, J Adolesc Health 2008 43 Suppl. 4 5 25 18809145
24. Determinants of Incidence and Clearance of High-Risk Human Papillomavirus Infections in Rural Rakai, Uganda. Safaeian M, Kiddugavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R, Cancer Epidemiol Biomarkers Prev 2008 17 6 1300 7 http://cebp.aacrjournals.org/ content/17/6/1300.abstract-target-4 10.1158/1055-9965.EPI-07-2678 18559545
25. Type-specific incidence, clearance and predictors of cervical human papillomavirus infections (HPV) among young women: a prospective study in Uganda. Banura C, Sandin S, van Doorn LJ, Quint W, Kleter B, Wabwire-Mangen F, Mbidde EK, Weiderpass E, Infectious Agents and Cancer 2010 5 7 10.1186/1750-9378-5-7 20380709
26. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. Namujju PB, Surcel HM, Kirnbauer R, Kaasila M, Banura C, Byaruhanga R, Muwanga M, Mbidde EK, Koskela P, Lehtinen M, Scand J Infect Dis 2010 42 6-7 522 6 10.3109/00365540903582426 20180681
27. Uganda Kaposi's Sarcoma Study Group. Human papillomaviruses and cancer in Uganda. Newton R, Bousarghin L, Ziegler J, Casabonne D, Beral V, Mbidde E, Carpenter L, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Touzé A, Coursaget P, Eur J Cancer Prev 2004 13 2 113 8 15100577 (Pubitemid 38585330)
28. HPV in Sub Saharan Africa. Clifford G, Franceschi S, Papillomavirus Report 2005 16 322 6 10.1179/095741905X49089 (Pubitemid 41715584)
29. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Mũoz N, Bosch FX, Lancet Infect Dis 2007 7 7 453 9 10.1016/S1473-3099(07)70158-5 17597569 (Pubitemid 46962343)
30. Chapter 8: HPV Vaccines. Frazer IH, Int J Gynecol & Obst 2006 94 Suppl 1 81 S88
31. Chapter 13: Current findings from prophylactic HPV vaccine trials. Koutsky LA, Harper DM, Vaccine 2006 24 Suppl 3 3/114 S3/121
32. Host and viral genetics and risk of cervical cancer: a review. Hildesheim A, Wang SS, Virus Res 2002 89 229 40 10.1016/S0168-1702(02)00191-0 12445662 (Pubitemid 35351541)
33. Chapter 5: Updating the natural history of HPV and anogenital cancer. Moscicki AB, Schiffman M, Kjaer S, Villa LL, Vaccine 2006 24 Suppl 3 3/42 51
34. UNGASS Country Progress Report. UNAIDS, http://www.unaids.org/en/ dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/ uganda-2010-country-progress-report-en.pdf
35. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. De Vuyst H, Lillo F, Broutet N, Smith JS, Eur J Cancer Prev 2008 17 6 545 54 10.1097/CEJ.0b013e3282f75ea1 18941376
36. Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness. Parham GP, Mwanahamuntu MH, Sahasrabuddhe VV, Westfall AO, King KE, Chibwesha C, Pfaendler KS, Mkumba G, Mudenda V, Kapambwe S, Vermund SH, Hicks ML, Stringer JSA, Chi BH, HIV Ther 2010 4 6 713 22 10.2217/hiv.10.52
37. Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A, the IMPAACT P1047 Protocol Team, J Acquir Immune Defic Syndr 2010 55 2 197 204 10.1097/QAI.0b013e3181de8d26 20574412
38. Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S, Temmerman M, Int J Cancer 2008 122 1 244 6 10.1002/ijc.23045 17764116 (Pubitemid 350210001)
39. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Louie KS, de Sanjosé S, Mayaud P, Trop Med Int Health 2009 14 10 1287 302 10.1111/j.1365-3156.2009. 02372.x 19772550
40. Efficacy of human papillomavirus (HPV)-16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study in young girls. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchner H, Castellsagué X, Teixeira JC, Skinner SK, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, the HPV PATRICIA STUDY GROUP, Lancet 2009 374 9686 301 14 10.1016/S0140-6736(09) 61248-4 19586656
41. Men's perceptions and knowledge of human papillomavirus (HPV) infection and cervical cancer. McPartland TS, Weaver BA, Lee SK, Koutsky LA, J Am Coll Health 2005 53 5 225 30 10.3200/JACH.53.5.225-230 15813233 (Pubitemid 40522511)
42. Importance of the male factor in cancer of the cervix. Skegg DC, Corwin PA, Paul C, Doll R, Lancet 1982 2 8298 581 3 6125731 (Pubitemid 12049488)
43. Male Sexual Behavior and Human Papillomavirus DNA: Key Risk Factors for Cervical Cancer in Spain. Bosch FX, Castellsague X, Munoz N, de Sanjose S, Ghaffari AM, Gonzlez LC, Gili M, Izarzugaza I, Viladiu P, Navarro C, Vergara A, Ascunce N, Guerrero E, Keerti V, Shah KV, J Natl Cancer Inst 1996 88 1060 7 10.1093/jnci/88.15.1060 8683637 (Pubitemid 26260492)
44. Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. Castellsagué X, Bosch FX, Mũoz N, Meijer CJLM, Shah KV, de Sanjosé S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S, the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group, N Engl J Med 2002 346 1105 1112 10.1056/NEJMoa011688 11948269 (Pubitemid 34984600)
45. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D, N Engl J Med 2011 364 401 411 10.1056/NEJMoa0909537 21288094
46. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. Garnett GP, J Infect Dis 2005 191 Suppl 1 97 S106 15627236
47. Approved budget estimates FY 2010/2011 Volume 1: Central Government Votes. GOU, Kampala 2010
48. Abuja declaration on HIV/AIDS, Tuberculosis and other related infectious diseases. OAU, Abuja 2001
49. Vaccine Investiment Strategy. GAVI Alliance, 2008
50. Position Paper: Human papillomavirus vaccines. WHO, http://www.who.int/ wer/2009/wer8415.pdf
51. HPV testing by hybrid capture. Emerging Issues of HPV Infections: From Science to Practice. Lorincz AT, Basel: Karger, Monsonego J, 2006 54 62
52. Use of a Hybrid Capture Assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, Li C, Lorincz A, Meehan MP, Wabwire-Mangen F, Gray RH, J Infect Dis 1999 180 4 1316 9 10.1086/315026 10479163 (Pubitemid 30070219)
53. Comparability of self-collected vaginal swabs and physcian collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Safaeian M, Kiddugave M, Gravitt PE, Ssekasanvu J, Murokora D, Sklar M, Serwadda D, Wawer MJ, Shah KV, Gray R, Sex Transm Dis 2007 34 7 429 36 17075437 (Pubitemid 46987946)
54. The Uganda study on HPV variants and genital cancers. Buonaguro FM, Tornesello ML, Salatiello I, Okong P, Buonaguro L, Beth-Giraldo E, Biryahwaho B, Sempala SD, Giraldo G, J Clin Virol 2000 19 1-2 31 41 10.1016/S1386-6532(00) 00131-1 11091146
55. Multiple infections in cases of cervical cancer from a high-incidence area in tropic Africa. Schmauz R, Okong P, de Villiers EM, Dennin R, Brade L, Lwanga SK, Owor R, Int J Cancer 1989 43 5 805 9 10.1002/ijc.2910430511 2714885 (Pubitemid 19138185)
56. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. Odida M, de Sanjosé S, Quint W, Bosch FX, Klaustermeier J, Weiderpass E, BMC Infect Dis 2008 8 85 10.1186/1471-2334-8-85 18577214 (Pubitemid 352025051)
57. Comparison of human papillomavirus detection between freshly frozen tissue and paraffin embedded tissue of invasive cervical cancer. Odida M, de Sanjosé S, Sandin S, Quiros B, Alemany L, Lloveras B, Quint W, Kleter B, Alejo M, van Doorn LJ, Weiderpass E, Infect Agent Cancer 2010 5 15 10.1186/1750-9378-5-15 20846370
58. Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis. Tobian AR, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, Charvat B, Ssempijja V, Riedesel M, Oliver AE, Nowak RG, Moulton LH, Chen MZ, Reynolds SJ, Wawer MJ, Gray RH, N Engl J Med 2009 360 1298 1309 10.1056/NEJMoa0802556 19321868
59. Circumcision of HIV-infected men: Effects on High Risk Human Papillomavirus Infections in a Randomized Trial in Rakai, Uganda. Serwadda D, Wawer MJ, Makumbi F, Kong X, Kigozi G, Gravitt P, Watya S, Nalugoda F, Ssempijja V, Tobian AAR, Kiwanuka N, Moulton LH, Sewankambo NK, Reynolds SJ, Quinn TC, Oliver ME, Iga B, Laeyendecker O, Gray RH, J Infect Dis 2010 201 10 1463 9 10.1086/652185 20370481
60. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. Gray RH, Serwadda D, Kong X, Makumbi F, Kigozi G, Gravitt PE, Watya S, Nalugoda F, Ssempijja V, Tobian AA, Kiwanuka N, Moulton LH, Sewankambo NK, Reynolds SJ, Quinn TC, Iga B, Laeyendecker O, Oliver AE, Wawer MJ, J Infect Dis 2010 201 10 1455 62 10.1086/652184 20370483